Facilitated By

San Antonio Medical Foundation

Research Project Qualification Form

556 Results Page 34 of 56

RANDOMIZED TRIAL OF TICAGRELOR IN SEVERE COMMUNITY ACQUIRED PNEUMONIA

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Malave,Adriel J
Funded by
VANDERBILT UNIVERSITY
Active Project
Infectious Disease
Clinical Care
Drug Discovery

IN SILICO SCREENING FOR INHIBITORS OF CARDS TOXIN FROM M. PNEUMONIAE

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Hart,Peter John
Funded by
WELCH FOUNDATION
Active Project
Infectious Disease
Basic Research

IDENTIFYING LIVER STAGE ANTIMALARIALS THAT DRIVE PROTECTIVE IMMUNITY

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Hart,Matthew J
Funded by
UT SAN ANTONIO
Active Project
Infectious Disease
Basic Research

RAPID PCR TO GUIDE ANTIBIOTIC THERAPY AT THE TIME OF PROSTATE BIOPSY

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Liss,Michael A
Funded by
AGENCY FOR HEALTHCARE RESEARCH & QUALITY
Active Project
Cancer
Infectious Disease
Clinical Care

A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial Of Emricasan (Idn-6556), An Oral Caspase Inhibitor, In Subjects With Non-Alcoholic Steatohepatitis (Nash) Fibrosis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva

This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive emricasan 50 mg BID, emricasan 5 mg BID or placebo BID.

Active Project
Infectious Disease
Clinical Care

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Investigate The Efficacy And Safety Of Mongersen (GED-0301) For The Treatment Of Subjects With Active Crohns Disease

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 treatment regimens of oral GED-0301 versus placebo in subjects with active CD (defined by a CDAI score ? 220 and ? 450 and a total SES-CD ? 6 at screening, or the ileum segmental SES-CD ? 4 at screening).

Active Project
Infectious Disease
Clinical Care

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study To Evaluate The Efficacy And Safety Of Elafibranor In Patients With Nonalcoholic Steatohepatitis (Nash) And Fibrosis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva

Randomized, double-blind, parallel groups (placebo or elafibranor [GFT505]) placebo-controlled study, evaluating the efficacy and safety of elafibranor 120 mg QD versus placebo in an adult NASH population with fibrosis.

Active Project
Infectious Disease
Clinical Care

A Phase III, Randomized, Multicenter, Double-Blind, Safety Study Of Ferumoxytol Compared To Ferric Carboxymaltose For The Treatment Of Iron Deficiency Anemia (IDA)

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva

This is a Phase III, randomized, double-blind, multicenter, safety study of 1.020 g of IV ferumoxytol, administered as 2 doses of 510 mg each, compared to 1.500 g of IV FCM, administered as 2 doses of 750 mg each for the treatment of iron deficiency anemia.

Active Project
Infectious Disease
Clinical Care

Adipose-Derived Stem Cell Sheet (ADSCs) Combined with an Advanced Collagen Matrix for Treatment of Chronic, Non-healing Diabetic Skin wounds

Southwest Research Institute

Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.

Principal Investigator(s)
Xingguo Cheng
Robert J. Christy
Denis Feliers
Funded by
San Antonio Medical Foundation
Collaborating Institutions
US Army Institute of Surgical Research
The University of Texas Health Science Center at San Antonio

This project aims to develop a new stem cell-based therapy for non-healing diabetic ulcers using a full-thickness skin defect animal model of type 2 diabetes. Bioactive cell sheets based on electrochemically aligned collagen matrix combined with ADSCs will be used to treat chronic, non-healing wounds.

Collaborative Project
Active Project
Infectious Disease
Diabetes and Obesity
Regenerative Medicine
Trauma
Basic Research
Clinical Care
Disease Modeling

ULTRASOUND MEDIATED DRUG DELIVERY IN 3D TISSUE MODEL QUANTIFIED BY PHOTOACOUSTIC TOMOGRAPHY

Southwest Research Institute

Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.

Principal Investigator(s)
Dr. Jian Ling
Funded by
Internally Funded
Collaborating Institutions
UTSA

Personalized medicine provides a unique opportunity for patients to receive optimized treatment efficacy through individually tailored and targeted therapies. The ability to control the release of therapeutics in targeted tissues with a desired spatial distribution and at an adjustable rate is essential for personalized medicine. However, it is extremely challenging to control the release of a therapeutic drug with the desired timing, while also monitoring the real-time drug distribution in optically turbid deep tissue.

Collaborative Project
Active Project
Infectious Disease
Cancer
Disease Modeling
Drug Discovery